Abstract
OBJECTIVE: Benzodiazepines are the mainstay of treatment for mild-to-moderate alcohol withdrawal in outpatient settings, but they can interact with alcohol, cause motor incoordination, or be abused. This study compared the therapeutic responses of the benzodiazepine lorazepam and the anticonvulsant carbamazepine for the outpatient treatment of acute alcohol withdrawal in terms of patients’ previous detoxification histories, and compared the effects of these 2 medications on drinking behaviors in the immediate postdetoxification period.
DESIGN: This was a randomized double-blind trial comparing patient responses to carbamazepine and lorazepam across 2 levels of detoxification histories (0–1 or ≥2 previous medicated detoxifications).
SETTING: A university medical center substance abuse clinic in Charleston, SC.
PATIENTS: One hundred thirty-six patients in moderate alcohol withdrawal were randomized. Major exclusions were significant hepatic or hematologic abnormalities and use of medications that could alter withdrawal symptoms.
INTERVENTIONS: Patients received 600–800 mg of carbamazepine or 6–8 mg of lorazepam in divided doses on day 1 tapering to 200 mg of carbamazepine or 2 mg of lorazepam.
MAIN OUTCOME MEASURES: The Clinical Institute Withdrawal Assessment for Alcohol-Revised was used to assess alcohol withdrawal symptoms on days 1 through 5 and postmedication at days 7 and 12. Daily drinking was measured by patient report using a daily drinking log and a breath alcohol level with each visit. Side effects were recorded daily.
RESULTS: Carbamazepine and lorazepam were equally effective at decreasing the symptoms of alcohol withdrawal. In the post-treatment period, 89 patients drank on at least 1 day; on average, carbamazepine patients drank less than 1 drink per drinking day and lorazepam patients drank almost 3 drinks per drinking day (P=.003). Among those with multiple past detoxifications, the carbamazepine group drank less than 1 drink per day on average and the lorazepam group drank about 5 drinks per day on average (P=.033). Lorazepam-treated patients had a significant rebound of alcohol withdrawal symptoms post-treatment (P=.007) and the risk of having a first drink was 3 times greater (P=.04) than for carbamazepine-treated patients. Twenty percent of lorazepam-treated patients had dizziness, motor incoordination, or ataxia and did not recognize their impairment. Twenty percent of carbamazepine-treated patients reported pruritus but no rash.
CONCLUSIONS: Carbamazepine and lorazepam were both effective in decreasing the symptoms of alcohol withdrawal in relatively healthy, middle-aged outpatients. Carbamazepine, however, was superior to lorazepam in preventing rebound withdrawal symptoms and reducing post-treatment drinking, especially for those with a history of multiple treated withdrawals.
Similar content being viewed by others
References
Stinnett J. Outpatient detoxification of the alcoholic. Intrl J Addictions. 1982;17:1031–46.
Miller W, Hester R. Inpatient alcoholism treatment: who benefits. Am Psychol. 1986;41:794–805.
Webb M, Unwin A. The outcome of outpatient withdrawal from alcohol. Br J Addiction. 1988;83:929–34.
Alterman A, Hayasida M, O’Brien C. Treatment response and safety of ambulatory medical detoxification. J Stud Alcohol. 1988;49:160–6.
Hayashida M, Alterman A, McLellan T, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med. 1989;320:358–65.
Klijnsma M, Cameron M, Burns T, McGuigan S. Outpatient alcohol detoxification — outcome after two months. Alcohol Alcohol. 1995;30:669–73.
Wiseman EJ, Henderson KL, Briggs MJ. Individualized treatment for outpatients withdrawing from alcohol. J Clin Psychiatry. 1998;59:289–93.
Whitfield CL, Thompson G, Lamb A, Spencer V, Pfeifer M, Browning-Ferrando M. Detoxification of 1,024 alcoholic patients without psychoactive drugs. JAMA. 1978;239:1409–10.
Hall W, Zador D. The alcohol withdrawal syndrome. Lancet. 1997;349:1897–900.
Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA. 1997;278:144–51.
Saitz R, O’Malley SS. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am. 1997;81:881–907.
Prater CD, Miller KE, Zylstra RG. Outpatient detoxification of the addicted or alcoholic patient. Am Fam Physician. 1999;60:1175–83.
Koch-Weser J, Sellers EM, Kalant H. Alcohol intoxication and withdrawal. N Engl J Med. 1976;294:757–62.
Björkqvist S, Isohanni M, Makela R, Malinen L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 1976;53:333–42.
Ritola E, Malinen L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiat Scand. 1981;64:254–9.
Flygenring J, Hansen J, Holst B, Petersen E, Sorensen A. Treatment of alcohol withdrawal symptoms in hospitalized patients: a randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal). Acta Psychiat Scand. 1984;69:398–408.
Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989;146:617–21.
Stuppaeck C, Pycha R, Miller C, Whitworth A, Oberbauer H, Fleischhacker W. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 1992;27:153–8.
Kranzler HR, Bauer LO, Hersh D, Klingerhoffer V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend. 1995;38:203–11.
Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21:86–92.
Brown ME, Anton RF, Malcolm R, Ballenger JC. Alcoholic detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988;23:507–14.
Lechtenburg R, Worner TM. Seizure risk with recurrent alcohol detoxification. Arch Neurol. 1990;47:535–8.
Lectenburg R, Worner TM. Relative kindling effect of detoxification and non-detoxification admissions in alcoholics. Alcohol Alcohol. 1991;26:221–5.
Lechtenburg R, Worner TM. Total ethanol consumption as a seizure risk factor in alcoholics. Acta Neurol Scand. 1992;85:90–4.
Booth B, Blow F. The kindling hypothesis: further evidence from a U.S. national survey of alcoholic men. Alcohol Alcohol. 1993;28:593–8.
Worner TM. Relative kindling effect of readmissions in alcoholics. Alcohol Alcohol. 1996;31:375–80.
Shaw GK, Waller S, Latham CJ, Dunn G, Thomson AD. The detoxification experience of alcoholic inpatients and predictors of outcome. Alcohol Alcohol. 1998;33:291–303.
Gross MM, Rosendlatt SM, Lewis E, Chartoff S, Malenowski B. Acute alcohol psychoses in related syndromes: psychosocial and clinical characteristics and their implications. Br J Addict. 1972;67:15–31.
Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndrome. Br J Psychiatry. 1978;133:1–14.
Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol. 1969;25:295–330.
Becker HC, Hale RL. Repeated episodes of ethanol withdrawal potentiate the severity of subsequent withdrawal seizures: an animal model of alcohol withdrawal “kindling.” Alcohol Clin Exp Res. 1993;17:94–8.
McCown TJ, Breese GR. Multiple withdrawals from chronic ethanol “kindles” inferior collicular seizure activity: evidence for kindling of seizures associated with alcoholism. Alcohol Clin Exp Res. 1990;14:394–9.
Veatch LM, Gonzales LP. Repeated ethanol withdrawal produces site-dependent increases in EEG spiking. Alcohol Clin Exp Res. 1996;20:262–7.
Folstein MF, Folstein SW, McHugh PR. Mini-Mental State: A practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Sullivan J, Swift R, Lewis D. Benzodiazepine requirements during alcohol withdrawal syndrome: clinical implications of using a standardized withdrawal scale. J Clin Psychopharmacol. 1991;11:291–5.
Skinner HA, Allen BA. Alcohol dependent syndrome: measurement and validation. J Abnorm Psychol. 1982;91:199–209.
Sobell MB, Sobell LC. Behavioral Treatment of Alcohol Problems. New York: Plenum Press; 1978.
Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS Systems for Mixed Models. Cary, NC: SAS Institute; 1996.
Kirk RE. Experimental Design: Procedures for the Behavioral Sciences. Monterey, Calif: Brooks/Cole; 1982.
Deutsch JA, Walton NY. Diazepam maintenance of alcohol preference during alcohol withdrawal. Science. 1977;198:307–9.
Hedlund L, Walstrom G. The effect of diazepam on voluntary alcohol intake in a rat model of alcoholism. Alcohol Alcohol. 1998;33:207–19.
O’Conner PG, Gottlieb LD, Kraus ML, Segal SR, Horwitz RI. Social and clinical features as predictors of outcome in outpatient alcohol withdrawal. J Gen Intern Med. 1991;6:312–6.
Kales A, Manfredi RL, Vgontzas AN, Bixler EO, Vela-Bueno A, Fee EC. Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines. Clin Pharmacol Ther. 1991;49:468–76.
Fontaine R, Chouinard G, Annable L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry. 1984;141:848–52.
MacKinnon GL, Parker WA. Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse. 1982;9:19–33.
DeVane CL, Nemeroff CB. Psychotropic drug interactions: 1999. Primary Psychiatry. 1999;6:39–88.
D’Onotrio G, Rathlev NK, Ulrich AS, Fish SS, Freeland ES. Lorazepam for the prevention of recurrent seizures related to alcohol. N Engl J Med. 1999;340:915–9.
Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998;155:1632.
Author information
Authors and Affiliations
Corresponding author
Additional information
This research was supported by the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism Center Grant no. AA10761.
Rights and permissions
About this article
Cite this article
Malcolm, R., Myrick, H., Roberts, J. et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J GEN INTERN MED 17, 349–355 (2002). https://doi.org/10.1007/s11606-002-0038-1
Issue Date:
DOI: https://doi.org/10.1007/s11606-002-0038-1